BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17390027)

  • 21. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
    Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
    Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.
    Kenley RA; Denissenko MF; Mullin RJ; Story J; Ekblom J
    Oncol Rep; 2008 May; 19(5):1113-21. PubMed ID: 18425366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice.
    Fermoselle C; García-Arumí E; Puig-Vilanova E; Andreu AL; Urtreger AJ; de Kier Joffé ED; Tejedor A; Puente-Maestu L; Barreiro E
    Exp Physiol; 2013 Sep; 98(9):1349-65. PubMed ID: 23625954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis.
    Gerlag DM; Ransone L; Tak PP; Han Z; Palanki M; Barbosa MS; Boyle D; Manning AM; Firestein GS
    J Immunol; 2000 Aug; 165(3):1652-8. PubMed ID: 10903776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase.
    Eley HL; Russell ST; Tisdale MJ
    Br J Cancer; 2007 Apr; 96(8):1216-22. PubMed ID: 17387345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
    Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
    Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutraceutical inhibition of muscle proteolysis: a role of diallyl sulphide in the treatment of muscle wasting.
    Olivan M; Busquets S; Figueras M; Fontes de Oliveira C; Toledo M; Sette A; Ventura da Silva P; Barberis P; Argilés JM; López-Soriano FJ
    Clin Nutr; 2011 Feb; 30(1):33-7. PubMed ID: 20655130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia.
    Zhang L; Tang H; Kou Y; Li R; Zheng Y; Wang Q; Zhou X; Jin L
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1105-15. PubMed ID: 23535871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of PARP activity in lung cancer-induced cachexia: Effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype.
    Chacon-Cabrera A; Mateu-Jimenez M; Langohr K; Fermoselle C; García-Arumí E; Andreu AL; Yelamos J; Barreiro E
    J Cell Physiol; 2017 Dec; 232(12):3744-3761. PubMed ID: 28177129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.
    McFarlane C; Plummer E; Thomas M; Hennebry A; Ashby M; Ling N; Smith H; Sharma M; Kambadur R
    J Cell Physiol; 2006 Nov; 209(2):501-14. PubMed ID: 16883577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation.
    Musolino V; Palus S; Tschirner A; Drescher C; Gliozzi M; Carresi C; Vitale C; Muscoli C; Doehner W; von Haehling S; Anker SD; Mollace V; Springer J
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):555-566. PubMed ID: 27239419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.
    Martinelli GB; Olivari D; Re Cecconi AD; Talamini L; Ottoboni L; Lecker SH; Stretch C; Baracos VE; Bathe OF; Resovi A; Giavazzi R; Cervo L; Piccirillo R
    Oncogene; 2016 Dec; 35(48):6212-6222. PubMed ID: 27212031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?
    Toledo M; Busquets S; Ametller E; López-Soriano FJ; Argilés JM
    J Cachexia Sarcopenia Muscle; 2011 Mar; 2(1):57-62. PubMed ID: 21475674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.
    Tessitore L; Costelli P; Baccino FM
    Biochem J; 1994 Apr; 299 ( Pt 1)(Pt 1):71-8. PubMed ID: 8166661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
    Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
    Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.
    Costelli P; Bossola M; Muscaritoli M; Grieco G; Bonelli G; Bellantone R; Doglietto GB; Baccino FM; Rossi Fanelli F
    Cytokine; 2002 Jul; 19(1):1-5. PubMed ID: 12200106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats.
    Oliveira AG; Gomes-Marcondes MC
    BMC Cancer; 2016 Jul; 16():418. PubMed ID: 27388367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis.
    Penner CG; Gang G; Wray C; Fischer JE; Hasselgren PO
    Biochem Biophys Res Commun; 2001 Mar; 281(5):1331-6. PubMed ID: 11243882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.
    Fuster G; Busquets S; Ametller E; Olivan M; Almendro V; de Oliveira CC; Figueras M; López-Soriano FJ; Argilés JM
    Cancer Res; 2007 Jul; 67(13):6512-9. PubMed ID: 17616713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
    Fontes-Oliveira CC; Busquets S; Toledo M; Penna F; Paz Aylwin M; Sirisi S; Silva AP; Orpí M; García A; Sette A; Inês Genovese M; Olivan M; López-Soriano FJ; Argilés JM
    Biochim Biophys Acta; 2013 Mar; 1830(3):2770-8. PubMed ID: 23200745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.